Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 373 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR 120 years of discovery: 10 ways we’ve changed the story for... February 2, 2022 How Writing Helped Me Cope During Cancer April 27, 2021 EMA Recommends Extension of Therapeutic Indications for Encorafenib and Binimetinib August 23, 2024 The future of research: meet three of our scientists working on... December 13, 2022 Load more HOT NEWS European Lung Cancer Congress 2024 Study Says Exercise Combats Side Effects of Chemo and Other Meds... Keto Molecule Offers Clue for Preventing Colorectal Cancer Gene Tied to Alzheimer’s May Be Associated with Cancer-Related Cognitive Problems
